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(Index Date was deﬁ ned as the earliest ACE). Patients age ≥18, ≥6 months eligibility 
pre- and post-Index Date, ≥1 statin ﬁ ll and no statin augmenting ﬁ ll 6 months before 
the Index Date, and sub-optimal baseline HDL-C (<40 or <50 mg/dL for men and 
women) or triglyceride (>150 or >200 mg/dL for diabetic and non-diabetic) were 
included. Cohorts were determined based on NER or EZE ﬁ lls within 6 months of 
the Index Date (Cohort ID Period). Patients with alternative lipid agents or coronary 
event during the Cohort ID Period were excluded. Outcomes included ASCER and 
event-related medical costs and were compared via generalized linear models. Multi-
variate analyses controlled for age, gender, health coverage, geography, co-morbidi-
ties, baseline lipids, and severity of initial ACE. RESULTS: A total of 328 patients 
added NER (n = 145) or EZE (n = 183) and met all study criteria. NER patients were 
less likely female (8% vs. 29%, P < 0.0001), had lower baseline LDL-C (81 ± 32 vs. 
112 ± 40; P < 0.0001) and HDL-C (34 ± 7 vs. 40 ± 9; P < 0.0001). Age (57 ± 8 vs. 
58 ± 10; P = 0.2020), Deyo-Charlson comorbidity index (0.6 ± 1.1 vs. 0.9 ± 1.4; P = 
0.0923) and triglycerides (185 ± 118 vs. 199 ± 94; P = 0.2531) were not statistically 
different. Compared to EZE, NER patients had a 57% decrease in ASCER (incidence 
ratio: 0.43, 95%CI: 0.24–0.77). Clinical ﬁ ndings corresponded with 87% reduction 
in adjusted annual event-related costs compared to EZE (0.13; 95% CI: 0.04–0.41). 
CONCLUSIONS: Among patients requiring lipid management, adopting a compre-
hensive lipid approach demonstrated lower ASCER compared to further reducing 
LDL-C, consequently reducing annual event-related medical costs following an ACE.
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OBJECTIVES: A side effect of implantable cardioverter deﬁ brillator (ICD) devices is 
inappropriate shocks. Shocks are painful, can potentially induce lethal arrhythmias 
and cause severe psychological trauma to cardiac arrhythmic patients. The objective 
of this study was to investigate the risk of inappropriate shocks in patients who receive 
ICD therapy. METHODS: A comprehensive literature search was conducted to iden-
tify studies describing ICD therapy and reporting inappropriate shock data. The 
analysis included studies of patients with implantation performed after 2002, having 
a minimum study population of 50 participants and a minimum 12 month follow up 
period. The database search was augmented by hand searching references of contem-
porary systematic reviews in the area of ICD therapy, to ensure all relevant studies 
were captured. Patient numbers from the identiﬁ ed studies were pooled and summary 
statistics were estimated. RESULTS: A total of 415 published articles were identiﬁ ed 
via the database search. Following abstract and full text review, 32 studies were 
included for data extraction and statistical analysis. a further 4 studies were included 
from the systematic review hand search. The 36 studies provided a combined total of 
807 patients. 16.2% (SD: 11.1) of patients experienced at least one inappropriate 
shock, this was reduced to 15.3% with exclusion of paediatric studies. The median 
duration of follow up was 2.6 years. The average number of inappropriate shocks per 
year for all patients is 0.4 (SD: 0.4). The frequency of inappropriate shocks amongst 
patients who experienced at least one inappropriate shock is 2.2 (SD: 1.7) per year. 
In 11 studies that present detailed information on the nature of shocks 32.9% (SD: 
22.9) of total shock events were recorded as inappropriate. CONCLUSIONS: A high 
proportion of patients in recent trials experienced inappropriate shocks. Future devel-
opment of ICD therapy should focus on the reduction of the inappropriate shock risk.
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OBJECTIVES: Clopidogrel with aspirin is used to prevent thrombosis. However, 
signiﬁ cant interpatient variability in platelet response to clopidogrel has been reported. 
As many as 33% of patients are considered to be clopidogrel non-responders (NRs). 
a recent meta-analysis has shown that clopidogrel resistance is associated with a 3.5-
fold increased risk of ischemic events. There are several platelet function assays (PFAs) 
available to assess clopidogrel resistance, the gold-standard being light transmission 
aggregometry (LTA). Other PFAs have been developed, including vasodilator-stimu-
lated phosphoprotein phosphorylation (VASP), and VerifyNow® (VN), the latter being 
a point-of-care assay. However PFAs are not frequently used in the clinical setting 
since they are expensive, and time- and labour-intensive. It is of interest to compare 
the reliability of various PFAs in the identiﬁ cation of clopidogrel NRs. METHODS: 
A MEDLINE search was conducted (1966–2010) using the following MeSH terms: 
Clopidogrel, Resistance, and Platelet Function Assay. Patient-based studies which 
compared the proportion of clopidogrel NRs using different PFAs were retrieved. 
RESULTS: Four studies were retrieved. Of these studies, 3 demonstrated signiﬁ cant 
heterogeneity among PFAs in their assessment of clopidogrel responsiveness. The 
proportion of clopidogrel NRs identiﬁ ed with the various PFAs ranged from 13%–
39%, 44%–69%, 35%–90%, and 69%–70% in the 4 studies respectively. CONCLU-
SIONS: The ability to identify clopidogrel NRs by different PFAs varies greatly 
according to the assay used. In addition, LTA and VASP are associated with poor 
quality control, expense and long turnaround times, and they are typically restricted 
to specialized laboratories in research hospitals. The inability of current PFAs to 
accurately assess clopidogrel resistance may place unidentiﬁ ed clopidogrel NRs at 
increased risk of ischemic events. The challenges and costs associated with such tests 
may be eliminated by newer therapies which have less response variability than 
clopidogrel.
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OBJECTIVES: To review and analyze evidence for the comparative cholesterol-
lowering efﬁ cacy of ezetimibe-statin combination therapy versus statin monotherapy 
in adults with primary hypercholesterolemia. METHODS: MEDLINE, EMBASE, and 
the Cochrane Central Register of Controlled Trials were searched to identify parallel-
group, randomised controlled trials of ezetimibe-statin combination therapy versus 
statin monotherapy, published between January 1993 and March 2010. Studies were 
selected using predeﬁ ned criteria including minimum treatment of 4 weeks. Two review-
ers conducted screening of articles, critical appraisal and data extraction, with a third 
reviewer resolving disagreements. Study quality was assessed using the Cochrane Col-
laboration “risk of bias” assessment tool. The difference between treatments in mean 
percentage change from baseline in low-density lipoprotein cholesterol (LDL-C) and 
proportion of patients attaining LDL-C treatment goal was analyzed. Data were com-
bined by pair-wise, direct comparison random effects meta-analysis, with heterogeneity 
assessed using the I2 statistic. RESULTS: Fifteen articles met selection criteria; 13 
studies involving over 5000 patients could be included in the meta-analyses. Data on 
simvastatin, atorvastatin and rosuvastatin were analyzed. There was a signiﬁ cantly 
greater percentage reduction in LDL-C levels in patients treated with ezetimibe-statin 
monotherapy compared with those treated with statin monotherapy (weighted mean 
difference: 14.11% [95% CI: 16.13, 12.1], P < 0.001), similarly, a greater proportion 
of patients achieved LDL-C goal when treated with ezetimibe-statin combination 
therapy compared with those treated with statin monotherapy (odds ratio 2.38 [95% 
CI: 1.89, 2.94], P < 0.001). The proportion of patients achieving LDL-C goal ranged 
from 12–83% (median 60%) in ezetimibe-statin arms of studies and from 2–52% 
(median 23%) in the statin monotherapy arms. CONCLUSIONS: The results indicate 
that ezetimibe-statin combination therapy is signiﬁ cantly more effective in reducing 
LDL-C levels than increasing the statin monotherapy dose, thereby enabling more 
patients to achieve their LDL-C goal.
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OBJECTIVES: Patients undergoing elective THR surgery are at an increased risk for 
VTEs. Even though dalteparin and enoxaparin have proven clinical effectiveness in 
placebo controlled studies, there have been no head-to-head trials to assess compara-
tive effectiveness. Meta-analytic techniques were used for an indirect statistical com-
parison on the safety and efﬁ cacy between dalteparin and enoxaparin in patients 
undergoing THR surgery. METHODS: A literature search of major databases was 
conducted from 1980 to 2009 for randomized placebo controlled trials evaluating 
both agents in THR patients. Binary outcomes (e.g. VTE rates) for the LMWH group 
relative to control group were statistically pooled using ﬁ xed or random effects models 
in cases of signiﬁ cant heterogeneity. In trials where a common control was used, 
indirect statistical comparisons between dalteparin and enoxaparin were performed 
using meta regression analysis with active drug (dalteparin or enoxaparin) as the 
primary independent variable. RESULTS: A total of nine placebo controlled enoxa-
parin (n = 5) and dalteparin (n = 4) trials met the inclusion criteria. The meta analysis 
of all trial data showed that THR patients treated with enoxaparin or dalteparin had 
a 54% VTE relative risk reduction compared to the placebo (RR = 0.46, p < 0.001). 
This beneﬁ t was achieved without a signiﬁ cant increase in the risk for major bleeds 
(RR = 1.14, p = 0.80), heparin induced thrombocytopenia (HIT) (RR = 0.83, p = 0.75) 
or death (RR = 0.77, p = 0.61). The indirect statistical comparison was not able to 
ﬁ nd signiﬁ cant differences between enoxaparin and dalteparin in terms of VTEs (p = 
0.86), risk of major bleeds (p = 0.46), HIT (p = 0.75) and death (p = 1.0). CONCLU-
SIONS: The ﬁ ndings of the analysis suggest comparable safety and efﬁ cacy between 
dalteparin and enoxaparin in THR patients. Therefore, treatment decisions should be 
based on other considerations such as patient or physician preference, ease of admin-
istration and cost.
